Endometrial cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• TP53 8
• PD-1 17
• HER2 13
• PTEN 3
• PI3K 7
• PD-L1 6
• mTOR 2
• AKT 2
• CTNNB1 1
• PIK3CA 6
• ARID1A 3
• BRCA1 2
• KRAS 5
• PARP 3
• VEGF 2
• CDK4/6 3
• ERK 0
• GLP-1 3
• STAT3 0
• TROP2 3
• BRCA2 1
• CTLA-4 2
• MAPK 0
• ESR1 0
• AR 0
• ATM 1
• AMPK 1
• AXL 2
• B7-H3 2
• COX-2 0
• FGFR 0
• IGF1R 0
• TIGIT 1
• BCL-2 0
• FTO 0
• GPX4 0
• HDAC 0
• HER3 1
• PALB2 1
• RAS 1
• BRAF 0
• EGFR 2
• EZH2 0
• JAK 0
• JNK 0
• KEAP1 1
• LAG-3 0
• MDM2 0
• MET 0
• MMP-9 0
• NLRP3 0
• PRAME 1
• PSMA 1
• SGLT2 1
• STING 0
• STK11 1
• APOE 0
• CD20 0
• CD47 0
• CDKN2A 0

24 of 62+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NICHD · R61

  Ultrasound-guided Ovarian Tissue Graft generation Platform to improve fertility outcomes

  Atera Medical· Mountain View, United States· US$377,257 awarded in fiscal year 2026· until Jun 2028

• NIH NCI · U01

  Collaborative Modeling to Identify Strategies to Improve US Breast Cancer Outcomes in an Era of Innovation

  University of Wisconsin-Madison· Madison, United States· US$1,839,480 awarded in fiscal year 2026· until Aug 2031

• NIH NINDS · R56

  The Mechanism of Trinucleotide Repeat Disease Expansions

  Ohio State University· Columbus, United States· US$551,250 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R34

  Reinforcing the Cancer Prevention Potential of Aspirin in Lynch Syndrome (ReCAPP-LS): Development and Piloting of an Electronic Decision Support Tool

  Research Inst of Fox Chase Can Ctr· Philadelphia, United States· US$314,079 awarded in fiscal year 2026· until Aug 2029

• NIH NCI · U01

  Comparative Modeling of Uterine Cancer

  Tufts Medical Center· Boston, United States· US$1,270,995 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Continuous Estrogen Monitoring Patch (EstroPatch)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution €321,301· until May 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Dencatistat, a first-in-class, tumour-agnostic, orally available CTPS1 inhibitor to treat gynaecologic tumours (STP938)

  Step Pharma· Paris, France· EU contribution €2,499,991· until Aug 2027

  The disease is named only in the funder's project summary, not in the title.

7 of 150 running projects, newest first. Listed amounts together: US$105.9m + €2.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Pfizer· Updated 4 Jun 2026

  “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”Registry text, quoted unchanged. Source

• Terminated

  BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

  NCT06321068· Bio-Thera Solutions· Updated 14 Aug 2025

  “Due to the adjustment of our company's research and development strategy, we are now prematurely terminating this project.”Registry text, quoted unchanged. Source

• Withdrawn

  Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

  NCT05419817· Haider Mahdi· Updated 27 Feb 2023

  “Slow Accrual”Registry text, quoted unchanged. Source

• Suspended

  A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

  NCT04042116· Clovis Oncology, Inc.· Updated 20 Dec 2022

  “Company decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  NCT06952504· Merck Sharp & Dohme LLC· Source

• Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

  NCT04165772· Memorial Sloan Kettering Cancer Center· Source

• Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

  NCT04106414· Memorial Sloan Kettering Cancer Center· Source

• DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  NCT06989112· AstraZeneca· Source

• A Study of Ivonescimab in People With Endometrial and Cervical Cancers

  NCT06925724· Memorial Sloan Kettering Cancer Center· Source

• Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

  NCT04634877· Merck Sharp & Dohme LLC· Source

• Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

  NCT06561308· Women's Hospital School Of Medicine Zhejiang University· Source

• Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  NCT07044336· AstraZeneca· Source

• Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

  NCT04463771· Incyte Corporation· Source

• Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

  NCT05173987· Merck Sharp & Dohme LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 8
• Organoids 3
• Mendelian Randomization Analysis 13
• CRISPR-Cas Systems 5
• Gene Expression Profiling 37
• Sequence Analysis, RNA 1
• Exome Sequencing 6
• Proteomics 17
• Metabolomics 7
• Mass Spectrometry 1
• Flow Cytometry 1
• Immunohistochemistry 85
• Liquid Biopsy 4
• Circulating Tumor DNA 9
• Xenograft Model Antitumor Assays 38
• Positron-Emission Tomography 4
• Magnetic Resonance Imaging 36
• Machine Learning 35
• Deep Learning 18
• Cohort Studies 82
• Genome-Wide Association Study 11

• Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway.

  Gynecol Oncol, Jan 2012

See which targets of this disease your abstract mentions, and go to the people working on them.